N@N

Gregory Renza Maintained (ACAD) at Buy with Increased Target to $33 on, Nov 3rd, 2023

Gregory Renza of RBC Capital, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $32 to $33 on, Nov 3rd, 2023.

Gregory has made no other calls on ACAD in the last 4 months.

There are 8 other peers that have a rating on ACAD. Out of the 8 peers that are also analyzing ACAD, 3 agree with Gregory's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $29 on, Monday, August 7th, 2023
• Jay Olson of "Oppenheimer" Reiterated at Hold and Held Target at $25 on, Thursday, August 3rd, 2023
• Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $27 on, Friday, July 14th, 2023

These are the ratings of the 5 analyists that currently disagree with Gregory

---

• Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $33 on, Tuesday, October 17th, 2023
• Tessa Romero of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $32 on, Tuesday, October 10th, 2023
• Sarah James of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $42 on, Tuesday, August 22nd, 2023
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $38 on, Thursday, August 3rd, 2023
• Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $33 on, Thursday, August 3rd, 2023

Contributing Sources

---